A5043414993- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Retinoids in leukemia and cellular processes
- Multiple Myeloma Research and Treatments
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Hematological disorders and diagnostics
- Epigenetics and DNA Methylation
- Hematopoietic Stem Cell Transplantation
- Histone Deacetylase Inhibitors Research
- Advanced biosensing and bioanalysis techniques
- Gene expression and cancer classification
- Digital Imaging for Blood Diseases
- Genomic variations and chromosomal abnormalities
- Blood disorders and treatments
- Mast cells and histamine
- Sarcoma Diagnosis and Treatment
- Molecular Biology Techniques and Applications
- RNA Research and Splicing
Munich Leukemia Laboratory (Germany)
2016-2025
Massachusetts General Hospital
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2022
Leukemia and Lymphoma Society
2022
Cleveland Clinic
2022
Kyoto University
2022
Cancer Institute (WIA)
2022
Ministero della Salute
2022
Institute of Biomedical Science
2022
Humanitas University
2022
High-throughput DNA sequencing significantly contributed to diagnosis and prognostication in patients with myelodysplastic syndromes (MDS). We determined the biological prognostic significance of genetic aberrations MDS. In total, 944 various MDS subtypes were screened for known/putative mutations/deletions 104 genes using targeted deep array-based genomic hybridization. 845/944 (89.5%) harbored at least one mutation (median, 3 per patient; range, 0-12). Forty-seven mutated TET2, SF3B1,...
Hairy-cell leukemia (HCL) is a well-defined clinicopathological entity whose underlying genetic lesion still obscure.We searched for HCL-associated mutations by performing massively parallel sequencing of the whole exome leukemic and matched normal cells purified from peripheral blood an index patient with HCL. Findings were validated Sanger in 47 additional patients HCL.Whole-exome identified five missense somatic clonal that confirmed on sequencing, including heterozygous mutation BRAF...
Abstract B-cell leukemia/lymphoma 2 (BCL-2) prevents commitment to programmed cell death at the mitochondrion. It remains a challenge identify those tumors that are best treated by inhibition of BCL-2. Here, we demonstrate acute myeloid leukemia (AML) lines, primary patient samples, and murine xenografts very sensitive treatment with selective BCL-2 antagonist ABT-199. In cells, median IC50 was approximately 10 nmol/L, occurred within hours. Our ex vivo sensitivity results compare favorably...
The Microarray Innovations in Leukemia study assessed the clinical utility of gene expression profiling as a single test to subtype leukemias into conventional categories myeloid and lymphoid malignancies.The investigation was performed 11 laboratories across three continents included 3,334 patients. An exploratory retrospective stage I designed for biomarker discovery generated whole-genome profiles from 2,143 patients with myelodysplastic syndromes. profiling-based diagnostic accuracy...
Acute myeloid leukemia (AML) carrying NPM1 mutations and cytoplasmic nucleophosmin (NPMc+ AML) accounts for about one-third of adult AML shows distinct features, including a unique gene expression profile. MicroRNAs (miRNAs) are small noncoding RNAs 19-25 nucleotides in length that have been linked to the development cancer. Here, we investigated role miRNAs biology NPMc+ AML. The miRNA was evaluated 85 de novo patients characterized subcellular localization/mutation status FLT3 using custom...
Purpose Several prognostic scoring systems have been proposed for chronic myelomonocytic leukemia (CMML), a disease in which some gene mutations—including ASXL1—have associated with poor prognosis univariable analyses. We developed and validated score overall survival (OS) based on mutational status standard clinical variables. Patients Methods genotyped ASXL1 up to 18 other genes including epigenetic (TET2, EZH2, IDH1, IDH2, DNMT3A), splicing (SF3B1, SRSF2, ZRSF2, U2AF1), transcription...
Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia (AML) that used for prognostic, predictive, monitoring, and efficacy-response assessments. The European LeukemiaNet (ELN) MRD Working Party evaluated standardization harmonization of ongoing manner has updated the 2018 ELN recommendations based on significant developments field. New revised were established during in-person online meetings, a 2-stage Delphi poll was conducted to optimize consensus. All are...
PURPOSE Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene ( FLT3-ITD) have a poor prognosis, frequently relapse, and die as result of AML. It is currently unknown whether maintenance therapy using FLT3 inhibitors, such multitargeted inhibitor sorafenib, improves outcome after HCT. PATIENTS AND METHODS In randomized, placebo-controlled, double-blind...